Loading
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Rapa Therapeutics LLC, now recruiting.
RAPA-201 Therapy of Solid Tumors is a phase 1/2 interventional study registered as NCT05144698 by Rapa Therapeutics LLC, with 37 participants planned, started 2021-08-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody). Conditions listed: Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity. No results are recorded here; the registry entry is the source.